New research into the fight against Dengue, an insect-borne tropical disease that infects up to 390 million people worldwide annually, may influence the development of anti-viral therapies that are effective against all four types of the virus.
The findings, led by researchers at the University of Bristol and published in the Journal of Biological Chemistry today [2 August], show for the first time that there may be significant differences in specific properties of the viral proteins for the four dengue virus types.
Due to the effects of globalisation, including increased travel and urbanisation of human populations and the expanded geographical distribution of the mosquito vector that is responsible for the transmission of viral infections to millions of people, the number of individuals afflicted with dengue is rising.
Infection with any one of the four types of dengue virus (DENV types 1 - 4) may result in a spectrum of illnesses ranging from dengue fever, a mild flu like illness which causes high fever and joint pains, to the potentially fatal dengue haemorrhagic fever. Despite intensive research, dengue disease is not wholly understood, and there are no vaccines or anti-viral treatments available that can safely or effectively control the disease.
Dr Andrew Davidson, Senior Virologist and lead researcher from the University of Bristol, and colleagues examined the nuclear localisation properties of the NS5 protein of all four DENV types and found that there are major differences in the cellular localisation of the viral NS5 protein for the four DENV types.
The four types of DENV are genetically distinct. Although they can all cause dengue disease, little is known about how the genetic differences between them may translate into differences in virus replication and pathogenesis.